Venus Remedies

Which are the latest news on Venus Remedies?

Why is Venus Remedies Ltd falling/rising?

As of 05-Sep, Venus Remedies Ltd's stock is experiencing a decline of 1.21% after two days of gains, but it has shown strong long-term performance with a 120.24% increase year-to-date. Despite today's drop, increased investor participation indicates ongoing interest in the stock.

As of 05-Sep, Venus Remedies Ltd's stock price is currently falling, with a change of -20.65, representing a decrease of 1.21%. This decline follows two consecutive days of gains, indicating a potential trend reversal. Despite this recent drop, the stock has shown strong performance over various time periods, including a year-to-date increase of 120.24% and a remarkable 265.64% rise over the past year. <BR><BR>Today's trading saw the stock reach an intraday high of Rs 1768.8, reflecting a 3.44% increase at that point. However, the weighted average price indicates that more volume was traded closer to the low price, suggesting some selling pressure. Additionally, while the stock is trading above its moving averages across multiple time frames, the recent performance today is described as inline with the sector, which may imply that broader market conditions are influencing the stock's movement.<BR><BR>Investor participation has increased, with delivery volume rising by 65.14% against the 5-day average, indicating that there is still interest in the stock despite the current decline. Overall, while Venus Remedies Ltd has experienced a drop in price today, its long-term performance remains strong, and the market dynamics suggest a complex interplay of factors at work.

Who are in the management team of Venus Remedies?

The management team of Venus Remedies includes Pawan Chaudhary (Chairman & Managing Director), Manu Chaudhary (Joint Managing Director), Peeyush Jain (Deputy Managing Director), and several independent directors, bringing diverse expertise to the company.

The management team of Venus Remedies includes the following key members:<BR><BR>1. **Pawan Chaudhary** - Chairman & Managing Director<BR>2. **Manu Chaudhary** - Joint Managing Director<BR>3. **Peeyush Jain** - Deputy Managing Director<BR>4. **Ashutosh Jain** - Executive Director<BR>5. **Gilbert Wenzel** - Independent Director<BR>6. **S. K. Chadha** - Independent Director<BR>7. **Neha Kodan** - Company Secretary & Compliance Officer<BR>8. **Navdeep Sud** - Independent Director<BR>9. **Savita Gupta** - Independent Director<BR>10. **Akshansh Chaudhary** - Whole-time Director<BR>11. **Nps Monga** - Independent Director<BR><BR>This team brings a diverse range of expertise and leadership to the company.

What does Venus Remedies do?

Venus Remedies Ltd is a pharmaceutical and biotechnology company focused on global injectable launches, with a market cap of INR 2,149 Cr and reported net sales of 179 Cr and net profit of 23 Cr for June 2026. Established in 1989, it operates in the micro-cap market.

Overview: <BR>Venus Remedies Ltd is a pharmaceutical and biotechnology company that specializes in the global launch of injectables and operates within the micro-cap market.<BR><BR>History: <BR>Incorporated in 1989, Venus Remedies Limited was initially known as Venus Glucose Pvt Ltd and became a Public Limited Company in 1994. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 179 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 23 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 2,149 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 19.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.61% <BR>Debt-Equity: -0.14 <BR>Return on Equity: 15.49% <BR>Price to Book: 3.29<BR><BR>Contact Details: <BR>Address: S C No 857 Cabin No 10 2nd Flr, N A C Manimajra Chandigarh Chandigarh ( U T ) : 160101 <BR>Email: investorgrievance@venusremedies.co <BR>Website: http://www.venusremedies.com

Who are the peers of the Venus Remedies?

Venus Remedies' peers include Fredun Pharma, Panacea Biotec, Indoco Remedies, Windlas Biotech, Shukra Pharma, Hester Bios, NGL Fine Chem, Sakar Healthcare, and Beta Drugs Ltd. In terms of performance, Venus Remedies has a good growth rate and excellent capital structure, with a 1-year return of 268.72%, while Fredun Pharma leads with a 279.00% return.

Peers: The peers of Venus Remedies are Fredun Pharma, Panacea Biotec, Indoco Remedies, Windlas Biotech, Shukra Pharma, Hester Bios, NGL Fine Chem, Sakar Healthcare, and Beta Drugs Ltd.<BR><BR>Quality Snapshot: Excellent management risk is observed at Fredun Pharma and Shukra Pharma, while Average management risk is found at Venus Remedies, Indoco Remedies, Windlas Biotech, Hester Bios, NGL Fine Chem, Sakar Healthcare, and Beta Drugs Ltd, and the rest. Growth is Excellent at Fredun Pharma and Shukra Pharma, Good at Venus Remedies, and Below Average at Panacea Biotec, Indoco Remedies, Windlas Biotech, Hester Bios, NGL Fine Chem, Sakar Healthcare, and the rest. Capital Structure is Excellent at Venus Remedies, Windlas Biotech, NGL Fine Chem, and Beta Drugs Ltd, while Below Average is seen at Panacea Biotec, Indoco Remedies, Hester Bios, and Average at Sakar Healthcare.<BR><BR>Return Snapshot: Fredun Pharma has the highest 1-year return at 279.00%, while Panacea Biotec has the lowest at -9.67%. Venus Remedies' 1-year return of 268.72% is significantly higher than Panacea Biotec's. Additionally, NGL Fine Chem is the only peer with a negative six-month return.

How big is Venus Remedies?

As of 31st August, Venus Remedies Ltd has a market capitalization of 2,149.00 Cr, with recent net sales of 811.27 Cr and a net profit of 116.18 Cr. Shareholder's funds are 560.95 Cr, and total assets amount to 715.72 Cr as of March 2025.

As of 31st August, Venus Remedies Ltd has a market capitalization of 2,149.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Venus Remedies reported Net Sales of 811.27 Cr and a Net Profit of 116.18 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 560.95 Cr and Total Assets of 715.72 Cr.

Should I buy, sell or hold Venus Remedies Ltd?

Are Venus Remedies Ltd latest results good or bad?

Venus Remedies Ltd's latest results are generally positive, showing a 30.38% year-on-year revenue growth to ₹178.86 crores and a 139.27% increase in net profit to ₹22.97 crores, despite a sequential decline due to a strong previous quarter. The improvement in operating margins to 19.12% indicates enhanced efficiency and market positioning.

Venus Remedies Ltd's latest results can be considered quite good overall, particularly from a year-on-year perspective. In the first quarter of FY27, the company reported a revenue growth of 30.38% year-on-year, reaching ₹178.86 crores. This growth is a strong indicator of operational momentum and market expansion.<BR><BR>Moreover, the net profit surged by an impressive 139.27% year-on-year to ₹22.97 crores, although it did experience a decline of 51.64% compared to the previous quarter. This sequential drop is largely attributed to a very strong base from the previous quarter, which had recorded a significantly higher profit.<BR><BR>Another positive aspect is the substantial improvement in operating margins, which expanded to 19.12% from 11.21% in the same quarter last year. This indicates enhanced operational efficiency and better pricing power in their injectable formulations business.<BR><BR>While the sequential decline in both revenue and profit may raise concerns, it appears to be a normalization following an extraordinary previous quarter rather than a sign of deteriorating fundamentals. Overall, the company is demonstrating strong growth and improving profitability metrics, making the latest results favorable in the context of its long-term performance.

When is the next results date for Venus Remedies Ltd?

The next results date for Venus Remedies Ltd is July 20, 2026.

The next results date for Venus Remedies Ltd is scheduled for July 20, 2026.

Is Venus Remedies overvalued or undervalued?

As of November 12, 2025, Venus Remedies is considered undervalued with an attractive valuation grade, highlighted by a low PE ratio of 11.46 and strong stock performance, significantly outperforming the Sensex.

As of 12 November 2025, the valuation grade for Venus Remedies has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently considered undervalued, particularly when compared to its peers in the pharmaceuticals and biotechnology sector. Key ratios include a PE ratio of 11.46, an EV to EBITDA of 5.29, and a PEG ratio of 0.06, all of which suggest that the stock is trading at a significant discount relative to its earnings growth potential.<BR><BR>In comparison to its peers, Venus Remedies stands out with a much lower PE ratio than Sun Pharma (35.94) and Divi's Lab (69.64), both of which are classified as expensive. Additionally, its EV to EBITDA ratio is considerably more attractive than those of its peers, reinforcing the undervaluation narrative. The company's recent stock performance has significantly outpaced the Sensex, with a year-to-date return of 70.13% compared to the Sensex's 8.10%, further supporting the conclusion that Venus Remedies is undervalued in the current market environment.

Is Venus Remedies technically bullish or bearish?

As of November 11, 2025, the trend is bullish with moderate strength, supported by daily moving averages and monthly indicators, though caution is advised due to mixed signals in shorter timeframes and a bearish RSI on the monthly chart.

As of 11 November 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with moderate strength. Key indicators driving this stance include the daily moving averages which are bullish, and the monthly Bollinger Bands and KST also indicating bullish momentum. However, the weekly MACD and KST are mildly bearish, suggesting some caution in the short term. The RSI on the monthly timeframe is bearish, indicating potential overbought conditions. Overall, while there are mixed signals in the shorter timeframes, the prevailing trend is bullish.

How has been the historical performance of Venus Remedies?

Venus Remedies has shown consistent growth in net sales and profits, with net sales increasing from 321.89 crore in March 2019 to 647.89 crore in March 2025, and profit after tax recovering to 45.32 crore in March 2025 from previous losses. The company's earnings per share improved significantly, reflecting overall resilience and positive financial performance.

Answer:<BR>The historical performance of Venus Remedies shows a trend of increasing net sales and profits over the years, with significant fluctuations in certain metrics.<BR><BR>Breakdown:<BR>Venus Remedies has demonstrated a consistent growth in net sales, rising from 321.89 crore in March 2019 to 647.89 crore in March 2025. The total operating income followed a similar trajectory, reaching 647.89 crore in March 2025, up from 555.51 crore in March 2023. The company's operating profit (PBDIT) also increased, peaking at 84.50 crore in March 2025, while profit before tax surged to 71.83 crore in the same period, compared to a loss of 29.73 crore in March 2019. Profit after tax reached 45.32 crore in March 2025, reflecting a recovery from previous years of losses, including a significant loss of 10.00 crore in March 2020. The company's earnings per share (EPS) improved to 33.9 in March 2025, up from a negative EPS of -23.16 in March 2019. On the balance sheet, total assets increased to 715.72 crore in March 2025, while total liabilities rose to 715.72 crore, indicating a balanced growth. Cash flow from operating activities showed a positive trend, with a net cash inflow of 27.00 crore in March 2024, following a negative cash flow in previous years. Overall, Venus Remedies has shown resilience and growth in its financial performance over the years.

How has been the historical performance of Venus Remedies?

Venus Remedies has shown strong historical performance, with net sales increasing from 321.89 crore in March 2019 to 652.89 crore in March 2025, and a significant turnaround in profitability, achieving a profit after tax of 45.32 crore in March 2025 compared to a loss of 10.00 crore in March 2020. The company also improved its financial stability, with total assets growing to 715.72 crore and positive cash flow from operating activities.

Answer:<BR>The historical performance of Venus Remedies shows a positive trend in net sales and profitability over the years, with significant improvements noted in the latest fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Venus Remedies has demonstrated a steady increase in net sales, rising from 321.89 crore in March 2019 to 652.89 crore in March 2025. This growth is accompanied by a consistent rise in total operating income, which reached 652.89 crore in March 2025, up from 341.46 crore in March 2020. The total expenditure, excluding depreciation, also increased, amounting to 584.35 crore in March 2025. Despite this, the operating profit (PBDIT) has improved, reaching 84.49 crore in March 2025, compared to 46.09 crore in March 2020. Profit before tax has shown a remarkable recovery, climbing to 71.82 crore in March 2025 from a loss of 8.03 crore in March 2020. Consequently, profit after tax also increased to 45.32 crore in March 2025, reflecting a significant turnaround from a loss of 10.00 crore in March 2020. The company's total assets grew to 715.72 crore in March 2025, while total liabilities decreased to 1.69 crore, indicating improved financial stability. Cash flow from operating activities has been positive, with a net cash inflow of 27.00 crore in March 2024, further supporting the company's favorable financial trajectory.

Who are the top shareholders of the Venus Remedies?

The top shareholders of Venus Remedies include Sunev Pharma Solutions Limited with 17.21%, individual investors with 46.81%, and notable public shareholder Pradeep Kumar Jain at 2.78%. There are no pledged promoter holdings or mutual fund investments in the company.

The top shareholders of Venus Remedies include Sunev Pharma Solutions Limited, which holds the highest promoter stake at 17.21%. Additionally, individual investors collectively hold 46.81% of the shares. Among public shareholders, Pradeep Kumar Jain is notable with a holding of 2.78%. The company also has participation from five foreign institutional investors (FIIs), who collectively own 1.34% of the shares. There are no pledged promoter holdings, and no mutual funds are currently involved with the company.

Has Venus Remedies declared dividend?

Yes, Venus Remedies Ltd has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of September 23, 2013. However, the dividend yield is 0%, indicating that returns are primarily from price appreciation rather than dividend income.

Venus Remedies Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 23 Sep 13<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 28.73%, with a dividend return of 0%, resulting in a total return of 28.73%.<BR><BR>Over the past year, the price return was 38.64%, with a dividend return of 0%, leading to a total return of 38.64%.<BR><BR>In the 2-year period, the price return was 89.69%, and the dividend return was 0%, culminating in a total return of 89.69%.<BR><BR>For the 3-year period, the price return was 94.53%, with a dividend return of 0%, resulting in a total return of 94.53%.<BR><BR>In the last 4 years, the price return was 31.32%, and the dividend return was 0%, giving a total return of 31.32%.<BR><BR>Over the past 5 years, the price return was an impressive 775.0%, with a dividend return of 0%, leading to a total return of 775.0%.<BR><BR>Overall, while Venus Remedies Ltd has declared a dividend, the dividend yield remains at 0%, indicating that the returns are primarily driven by price appreciation rather than dividend income. The significant total returns over various periods highlight strong price performance.